Future Medical EXPO【Hosted by Osaka Prefecture】
-The world-leading ecosystem of Osaka-Kansai-

Hirofumi Yoshimura

Governor of Osaka Prefecture

Martina Hirayama

State Secretary for Education, Research and Innovation

Studied chemistry at ETH Zurich, the University of Fribourg and Imperial College London, earning her doctorate in technical sciences at ETH. After postgraduate studies in business economics, she led the Polymer Chemistry Group at ETH and co-founded a start-up in coating technologies, serving as CEO until 2008. From 2003, she was professor of industrial chemistry at ZHAW, later Director of the School of Engineering and head of International Affairs. She also held leadership roles at METAS, Innosuisse, and the Swiss National Science Foundation, and contributed to several national and international boards. Since January 2019, she has been Head of the State Secretariat for Education, Research and Innovation (SERI) at the Federal Department of Economic Affairs, Education and Research.

Yoshiki Sawa

President of the Organization of Future Medicine
Director of Osaka Police Hospital
Honorary Professor, Osaka University

Graduated from Osaka University School of Medicine in 1980 and joined the First Department of Surgery at the same university. Studied in Germany as a Humboldt Foundation Fellow at the Max Planck Institute, specializing in cardiac physiology and cardiac surgery.
Previously served as Professor and Chair of Cardiovascular and Thoracic Surgery at Osaka University Graduate School of Medicine, Director of the Center for Advanced Medical Innovation at Osaka University Hospital, Dean of Osaka University School of Medicine, President of the Japanese Society for Regenerative Medicine, and President of the Japanese Association for Thoracic Surgery.
Currently serves as President of the Organization for the Promotion of Future Medicine, Director of Osaka Police Hospital, and Professor Emeritus at Osaka University. He is also scheduled to serve as President of the 32nd Japan Medical Congress in 2027. Recipient of the Medal with Purple Ribbon in 2020.

Shinichiro Komoto

Partner, Eight Roads Ventures Japan

With deep expertise in the healthcare space, Shinichiro has led healthcare investments at Eight Roads Ventures Japan since 2017. Before that, during his long tenure at Mitsui & Co., he gained hands-on experience in healthcare investments, M&A, and managing subsidiaries across the U.S., Asia, and Japan.
Today, as an outside director of several portfolio companies, he works closely with founders—helping them scale globally. Passionate about nurturing Japanese healthcare startups with worldwide potential, he brings both strategy and support to the table. He holds a B.S. in Electrical Engineering from Tokyo Metropolitan University and completed an executive education program at INSEAD.

Dan Kemp

CEO, Shinobi Therapeutics, Inc.

Dr. Dan Kemp is an accomplished researcher with over 30 publications who built his drug discovery career at Novartis, Merck and Takeda over 20 years leading pipeline initiatives from discovery through early clinical development. Prior to joining Shinobi Therapeutics, Dan was CEO of cell therapy company Wugen Inc, and previous to that was responsible for negotiating and transacting many of Takeda's strategic cell therapy partnerships.
Dr. Kemp received his BSc and Ph.D. in molecular pharmacology from the University of Kent at Canterbury, UK. He was awarded a Howard Hughes Fellowship at Harvard Medical School and carried out his postdoc research on GLP-1 and pancreatic beta cells with Joel Habener at Massachusetts General Hospital.

Brenda Renata Kwak

Professor, University of Geneva, and Research Council member, Swiss National Science Foundation

Dr. Brenda Kwak is full professor in the Department of Pathology and Immunology at the Faculty of Medicine of the University of Geneva, Switzerland. After her medical studies at the University of Amsterdam in the Netherlands, she obtained a Ph.D. in the field of Medical Physiology from the same institution in 1993. Following postdoctoral training at the Universities of Utrecht and Geneva, she established her own research group in 2003 in Switzerland with the support of a Swiss National Science Foundation (SNSF) professorship. Professor Kwak chairs the Programme Committee International Cooperation of the National Research Council SNSF.

Chiemi Kamakura

President and CEO, Agatha Inc. Chiemi

Born in 1974 in Aichi Prefecture, currently residing in Tokyo. After completing her graduate studies at Nagoya Institute of Technology, she joined the Ministry of Internal Affairs and Communications, specifically the Telecommunications Bureau. In 2001, she transitioned to Hitachi, Ltd., where she was responsible for developing new business initiatives and designing foundational solutions for pharmaceutical and medical institutions, as well as managing related projects.
In 2011, she became the Japan Country Manager for NextDocs Corporation, a U.S.-based venture specializing in document management systems for pharmaceutical companies. In October 2015, she founded Agatha Inc. and assumed the role of President and CEO. She holds an MBA from Rice University in the United States and also serves as a part-time lecturer at her alma mater, Nagoya Institute of Technology.
In November 2024, she was honored with two prestigious awards: the “Woman of the Year 2025” presented by Nikkei WOMAN, and the “Tokyo Woman CEO Award” in the Sustainable Growth category, hosted by the Tokyo Metropolitan Government.

Mitsuru Miyata

President and CEO, MIYATA INSTITUTE of TECHNOLOGIES

After graduating from the University of Tokyo with a degree in science, he joined Nikkei Inc., where he helped launch Nikkei Biotech and served as editor-in-chief. He advanced internet initiatives and healthcare/bio information services while holding visiting professorships at several universities. After leaving Nikkei BP, he founded Miyata Research and Healthcare Innovation, producing global conferences. He now serves as Special Advisor to ARK Therapies.